Coloplast A/ S stock (DK0060448595): Medical devices leader navigates chronic care demand

Coloplast A/S maintains its position as a key player in the medical devices sector, focusing on products for chronic care needs such as ostomy bags, continence solutions, and wound care. The company reported stable demand in its core markets during the fiscal year ending September 30, 2025, with revenue growth driven by volume increases in North America, according to Coloplast IR as of November 2025.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

Coloplast A/S: core business model

Coloplast A/S develops and markets medical devices and services primarily targeting chronic care conditions. Its portfolio centers on ostomy care, which includes pouches and accessories for patients with stomas; continence care for urinary and bowel management; and interventional urology products like catheters. Wound and skin care rounds out the offerings. The company operates a direct-to-consumer model in many markets, emphasizing patient-centric innovation and support services.

Founded in 1957 in Denmark, Coloplast has expanded globally, with manufacturing sites in Europe, the US, and Asia. It prioritizes research and development, investing around 8-10% of revenue annually in new product development, as detailed in its annual report for the period ended September 30, 2025, published November 2025 on Coloplast IR as of November 2025.

Main revenue and product drivers for Coloplast A/S

Ostomy care remains the largest segment, accounting for roughly 45% of revenue in the fiscal year to September 2025, followed by continence care at about 35%. North America contributes over 40% of total sales, benefiting from an aging population and rising prevalence of chronic conditions like colorectal cancer and incontinence. Growth in this region was 7% in local currencies for that period, per the company's financial statements.

Key products include SpeediCath catheters for intermittent self-catheterization and SenSura Mio ostomy pouches, which feature adaptive sizing technology. These innovations drive market share gains, with Coloplast holding leading positions in most mature markets. Emerging markets in Asia and Latin America provide additional growth vectors through volume expansion.

Industry trends and competitive position

The global chronic care market is expanding due to demographic shifts, with the US ostomy care market projected to grow at 5% CAGR through 2030, according to MarketsandMarkets as of 2025. Competitors include Convatec, Hollister, and B. Braun, but Coloplast differentiates through its 'People First' strategy, focusing on patient outcomes and digital health integrations like the Coloplast Care app.

In the US, where Medicare reimbursements influence adoption, Coloplast's strong compliance and evidence-based product claims support steady penetration. Its balance sheet remains robust, with net debt to EBITDA below 2.5x as of September 2025.

Why Coloplast A/S matters for US investors

Coloplast A/S offers US investors exposure to defensive healthcare growth without direct US listing, via OTC trading (CLPBY) or international brokers. The company's 40%+ revenue from North America ties its performance to US healthcare spending trends, which rose 4.1% in 2025 per CMS data. Dividend payouts, with a 2025 yield around 2.5% in DKK terms, appeal to income-focused portfolios amid volatile equities.

Regulatory stability in the US, post-FDA approvals for new catheter lines in 2025, underscores its relevance. US investors track Coloplast for insights into medtech resilience during economic cycles.

Conclusion

Coloplast A/S sustains its leadership in chronic care medtech through innovation and geographic expansion, with North American strength bolstering revenue stability. Investors monitor upcoming quarterly updates for sustained volume growth amid healthcare tailwinds. The company's focus on patient needs positions it well in a maturing market.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.